ArticleGastroenterology research and practice2014
Identification of Aberrantly Expressed miRNAs in Gastric Cancer.
Article in Gastroenterology research and practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Investigating the relationship between depression and breast cancer: observational and genetic analyses.BMC medicine · 2023Pooled it
- Effect of miR-4270 on Tumorigenicity in Gastric Cancer Stem Cells via the Wnt Signaling Pathway.Advanced biomedical research · 2025Article
- miR-548 predicts clinical prognosis and functions as a tumor promoter in gastric cancer.Clinical and experimental medicine · 2023Article
- miR-514a promotes neuronal development in human iPSC-derived neurons.Frontiers in cell and developmental biology · 2023Article
- Status of diagnosis and treatment of esophageal cancer and non-coding RNA correlation research: a narrative review.Translational cancer research · 2021Review
- MACE-Seq-based coding RNA and TrueQuant-based small RNA profile in breast cancer: tumor-suppressive miRNA-1275 identified as a novel marker.BMC cancer · 2021Article
- miR-34a mimic or pre-mir-34a, which is the better option for cancer therapy? KatoIII as a model to study miRNA action in human gastric cancer cells.Cancer cell international · 2021Article
- Cervical Cancer Stem-Like Cell Transcriptome Profiles Predict Response to Chemoradiotherapy.Frontiers in oncology · 2021Article
- MicroRNA heterogeneity in melanoma progression.Seminars in cancer biology · 2019Review
- The Diverse Oncogenic and Tumor Suppressor Roles of microRNA-105 in Cancer.Frontiers in oncology · 2019Review
- Reduced miR-105-1 levels are associated with poor survival of patients with non-small cell lung cancer.Oncology letters · 2017Article
- Transcriptome profiling reveals miR-9-3p as a novel tumor suppressor in gastric cancer.Oncotarget · 2017Article
- Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review.World journal of experimental medicine · 2015Review
- Identification of low miR-105 expression as a novel poor prognostic predictor for human glioma.International journal of clinical and experimental medicine · 2015Article
- miR-3196 acts as a Tumor Suppressor and Predicts Survival Outcomes in Patients With Gastric Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The noncoding components of the genome, including miRNA, can contribute to pathogenesis of gastric cancer. Their expression has been profiled in many human cancers, but there are a few published studies in gastric cancer. It is necessary to identify novel aberrantly expressed miRNAs in gastric cancer. In this study, the expression profile of 1891 miRNAs was analyzed using a miRCURY array LNA miRNA chip from three gastric cancer tissues and three normal tissues. The expression levels of 4 miRNAs were compared by real-time PCR between cancerous and normal tissues. We found that 31 miRNAs are upregulated in gastric cancer (P < 0.05) and 10 miRNAs have never been reported by other studies; 30 miRNA are downregulated (P < 0.05) in gastric cancer tissues. Gene ontology analysis revealed that those dysregulated miRNAs mainly take part in regulating cell proliferation. The levels of has-miR-105, -213∗, -514b, and -548n were tested by real-time PCR and have high levels in cancerous tissues. Here, we report a miRNA profile of gastric cancer and provide new perspective to understand this malignant disease. This novel information suggests the potential roles of these miRNAs in the diagnosis, prognosis biomarkers, or therapy targets of gastric cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.